IOVA Q4 2022 Earnings — Iovance Biotherapeutics, Inc. Revenue & Financial Results | Market Cap Arena

IOVAIovance Biotherapeutics, Inc.

$2B

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$107M

Net Income

-$105M

EPS (Diluted)

$-0.62

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$78M

Free Cash Flow

-$81M

Stock-Based Comp.

$20M

Balance Sheet

Total Assets

$664M

Total Liabilities

$164M

Stockholders' Equity

$500M

Cash & Equivalents

$232M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$107M	-$99M	-7.6%
Net Income	-$105M	-$99M	-6.0%